Adial Pharmaceuticals, Inc. (ADIL)

NASDAQ: ADIL · IEX Real-Time Price · USD
3.260
+1.220 (59.80%)
At close: Mar 1, 2024, 4:00 PM
2.870
-0.390 (-11.96%)
After-hours: Mar 1, 2024, 7:59 PM EST
59.80%
Market Cap 5.42M
Revenue (ttm) n/a
Net Income (ttm) -6.07M
Shares Out 1.66M
EPS (ttm) -5.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,280,127
Open 3.129
Previous Close 2.040
Day's Range 2.700 - 4.170
52-Week Range 0.770 - 15.000
Beta 1.30
Analysts Strong Buy
Price Target 150.00 (+4,501.23%)
Earnings Date Mar 28, 2024

About ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2018
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ADIL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for ADIL stock is "Strong Buy" and the 12-month stock price forecast is $150.0.

Price Target
$150.0
(4,501.23% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapi...

2 days ago - GlobeNewsWire

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

New patent strengthens Adial's patent portfolio and covers AD04's unique ability to target the serotonin transporter gene for the potential treatment of opioid use disorder New patent strengthens Adia...

4 days ago - GlobeNewsWire

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

CHARLOTTESVILLE, VA / ACCESSWIRE / February 15, 2024 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)(NASDAQ:ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on develop...

17 days ago - Accesswire

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence Expands patent estate covering Adial's unique molecular gene...

19 days ago - GlobeNewsWire

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Highly Experienced Pharma Commercial and Business Development Executive in Addiction Treatment Space Joins Leadership Team While Continuing as Board Member Highly Experienced Pharma Commercial and Bus...

6 weeks ago - GlobeNewsWire

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

CHARLOTTESVILLE, Va., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

2 months ago - GlobeNewsWire

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

CHARLOTTESVILLE, Va., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

3 months ago - GlobeNewsWire

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Advancing Discussions with Potential Strategic Partners Received Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award Closed $4 Mill...

3 months ago - GlobeNewsWire

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

CHARLOTTESVILLE, Va., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

4 months ago - GlobeNewsWire

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Experts agree that there are benefits to reductions in drinking, supporting the ongoing development of non-abstinence-based therapies to treat alcohol use disorder Experts agree that there are benefit...

4 months ago - GlobeNewsWire

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

4 months ago - GlobeNewsWire

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

CHARLOTTESVILLE, Va., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies...

4 months ago - GlobeNewsWire

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

CHARLOTTESVILLE, VA / ACCESSWIRE / October 19, 2023 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies f...

4 months ago - Accesswire

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD patients Allowed claims cover the detection of select genotypes for use of AD04 to treating AUD and OUD p...

4 months ago - GlobeNewsWire

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Frost & Sullivan recognizes Adial for its best practices in precision medicine for the addiction disorders industry Frost & Sullivan recognizes Adial for its best practices in precision medicine for t...

4 months ago - GlobeNewsWire

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Pre-registration for the LinkedIn Live event will begin on Thursday, September 28th Industry experts to discuss the need for non-abstinence-based therapies in Alcohol Use Disorder (AUD) CHARLOTTESVILL...

5 months ago - GlobeNewsWire

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

6 months ago - GlobeNewsWire

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

CHARLOTTESVILLE, Va., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

6 months ago - GlobeNewsWire

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

CHARLOTTESVILLE, Va., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

6 months ago - GlobeNewsWire

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Reported Positive Feedback from US and EU Regulatory Meetings Sale of Purnovate Significantly Reduces Cash Burn Rate Charlottesville, Va., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....

6 months ago - GlobeNewsWire

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float

Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023 Common Stock Will Begin Trading on Split-Adjusted Basis on August 7, 2023

7 months ago - GlobeNewsWire

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

CHARLOTTESVILLE, Va., July 11, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the developm...

8 months ago - GlobeNewsWire

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

CHARLOTTESVILLE, Va., June 01, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing t...

9 months ago - GlobeNewsWire

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Conducted meetings with U.S. and select European regulatory agencies Received Notice of Exercise and upfront cash of $0.45 million from Advocate for the sale of Purnovate assets and business Ended 202...

10 months ago - GlobeNewsWire

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate's Assets and Business

Adial to receive potential development and commercial milestone payments of up to $83 million on the first three compounds plus 19.9% equity stake and ongoing royalties Adial to receive potential deve...

10 months ago - GlobeNewsWire